Sarepta Therapeutics, Inc. (0L35.L)
USD 53.05
(-7.49%)
USD 53.05
(-7.49%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 322.85 Million USD | 58.29% |
| 2022 | 203.96 Million USD | 9.54% |
| 2021 | 186.21 Million USD | -19.72% |
| 2020 | 231.96 Million USD | 35.35% |
| 2019 | 171.37 Million USD | 36.62% |
| 2018 | 125.44 Million USD | 50.04% |
| 2017 | 83.6 Million USD | 552.5% |
| 2016 | 12.81 Million USD | -52.32% |
| 2015 | 26.87 Million USD | -19.7% |
| 2014 | 33.46 Million USD | 361.59% |
| 2013 | 7.25 Million USD | 724999900.0% |
| 2012 | 1.00 USD | 100.0% |
| 2011 | -3.63 Million USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | 0.0% |
| 1995 | - USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 373.53 Million USD | 15.69% |
| 2024 Q2 | 485.79 Million USD | 30.06% |
| 2023 Q1 | 202.67 Million USD | -0.63% |
| 2023 FY | 322.85 Million USD | 58.29% |
| 2023 Q4 | 322.85 Million USD | 32.31% |
| 2023 Q3 | 244.01 Million USD | 7.55% |
| 2023 Q2 | 226.87 Million USD | 11.94% |
| 2022 Q2 | 208.09 Million USD | 4.57% |
| 2022 Q3 | 221.19 Million USD | 6.29% |
| 2022 Q4 | 203.96 Million USD | -7.79% |
| 2022 FY | 203.96 Million USD | 9.54% |
| 2022 Q1 | 198.99 Million USD | 6.87% |
| 2021 Q4 | 186.21 Million USD | -35.45% |
| 2021 Q1 | 240.33 Million USD | 3.61% |
| 2021 Q2 | 268.75 Million USD | 11.83% |
| 2021 Q3 | 288.46 Million USD | 7.33% |
| 2021 FY | 186.21 Million USD | -19.72% |
| 2020 Q3 | 220.11 Million USD | 22.53% |
| 2020 FY | 231.96 Million USD | 35.35% |
| 2020 Q2 | 179.65 Million USD | 3.74% |
| 2020 Q4 | 231.96 Million USD | 5.38% |
| 2020 Q1 | 173.16 Million USD | 1.04% |
| 2019 FY | 171.37 Million USD | 36.62% |
| 2019 Q2 | 156.56 Million USD | 11.46% |
| 2019 Q3 | 166.36 Million USD | 6.25% |
| 2019 Q4 | 171.37 Million USD | 3.02% |
| 2019 Q1 | 140.46 Million USD | 11.97% |
| 2018 FY | 125.44 Million USD | 50.04% |
| 2018 Q2 | 104.12 Million USD | 4.78% |
| 2018 Q1 | 99.37 Million USD | 18.86% |
| 2018 Q3 | 115.81 Million USD | 11.23% |
| 2018 Q4 | 125.44 Million USD | 8.31% |
| 2017 Q2 | 41.75 Million USD | 37.15% |
| 2017 Q1 | 30.44 Million USD | 137.61% |
| 2017 FY | 83.6 Million USD | 552.5% |
| 2017 Q4 | 83.6 Million USD | 29.23% |
| 2017 Q3 | 64.69 Million USD | 54.94% |
| 2016 Q1 | 26.5 Million USD | -1.36% |
| 2016 Q2 | 24.89 Million USD | -6.1% |
| 2016 Q3 | 2.92 Million USD | -88.27% |
| 2016 FY | 12.81 Million USD | -52.32% |
| 2016 Q4 | 12.81 Million USD | 338.65% |
| 2015 FY | 26.87 Million USD | -19.7% |
| 2015 Q3 | 18.83 Million USD | -16.81% |
| 2015 Q2 | 22.63 Million USD | -5.55% |
| 2015 Q1 | 23.96 Million USD | -28.38% |
| 2015 Q4 | 26.87 Million USD | 42.7% |
| 2014 FY | 33.46 Million USD | 361.59% |
| 2014 Q2 | 4 Million USD | -44.83% |
| 2014 Q3 | 4 Million USD | 0.0% |
| 2014 Q4 | 33.46 Million USD | 736.63% |
| 2014 Q1 | 7.25 Million USD | 0.0% |
| 2013 FY | 7.25 Million USD | 724999900.0% |
| 2013 Q3 | 7.25 Million USD | 0.0% |
| 2013 Q2 | 7.25 Million USD | 724999900.0% |
| 2013 Q1 | 1.00 USD | 0.0% |
| 2013 Q4 | 7.25 Million USD | 0.0% |
| 2012 Q4 | 1.00 USD | 100.0% |
| 2012 Q3 | -2.47 Million USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 FY | 1.00 USD | 100.0% |
| 2011 Q1 | -13.57 Million USD | 0.0% |
| 2011 Q2 | -10.89 Million USD | 19.77% |
| 2011 Q3 | -4.26 Million USD | 60.82% |
| 2011 Q4 | - USD | 100.0% |
| 2011 FY | -3.63 Million USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q3 | - USD | 100.0% |
| 2003 Q2 | -437.27 Thousand USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1998 Q4 | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1997 Q1 | - USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| 1996 Q4 | - USD | 0.0% |
| 1995 FY | - USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| uniQure N.V. | 12.02 Million USD | -2585.121% |
| Agios Pharmaceuticals, Inc. | 19.07 Million USD | -1592.488% |
| Amicus Therapeutics, Inc. | 59.69 Million USD | -440.839% |
| Atara Biotherapeutics, Inc. | 9.7 Million USD | -3226.386% |
| bluebird bio, Inc. | 22.91 Million USD | -1308.696% |
| Cara Therapeutics, Inc. | 2.82 Million USD | -11344.842% |
| Imunon, Inc. | - USD | -Infinity% |
| Editas Medicine, Inc. | - USD | -Infinity% |
| IQVIA Holdings Inc. | - USD | -Infinity% |
| Mettler-Toledo International Inc. | 385.86 Million USD | 16.329% |
| Myriad Genetics, Inc. | 20.1 Million USD | -1506.264% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | -742.974% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | -317.087% |
| Verastem, Inc. | - USD | -Infinity% |
| Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 96.119% |
| Waters Corporation | 516.23 Million USD | 37.459% |
| Thermo Fisher Scientific Inc. | 5.08 Billion USD | 93.655% |
| Biogen Inc. | 2.52 Billion USD | 87.226% |
| Nektar Therapeutics | 16.1 Million USD | -1905.211% |
| Perrigo Company plc | 1.14 Billion USD | 71.701% |
| Dynavax Technologies Corporation | 53.29 Million USD | -505.853% |
| Illumina, Inc. | 587 Million USD | 44.998% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Iovance Biotherapeutics, Inc. | 10.37 Million USD | -3012.794% |
| Heron Therapeutics, Inc. | 42.11 Million USD | -666.704% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 1.1 Billion USD | 70.84% |
| Sangamo Therapeutics, Inc. | - USD | -Infinity% |
| Evolus, Inc. | 10.99 Million USD | -2835.616% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Aclaris Therapeutics, Inc. | - USD | -Infinity% |
| Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | 87.489% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | -391.991% |
| FibroGen, Inc. | 41.56 Million USD | -676.757% |
| Agilent Technologies, Inc. | 1.03 Billion USD | 68.685% |
| OPKO Health, Inc. | 65.69 Million USD | -391.436% |
| Homology Medicines, Inc. | - USD | -Infinity% |
| Geron Corporation | - USD | -Infinity% |
| Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | -262.169% |
| Exelixis, Inc. | 17.32 Million USD | -1763.759% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | - USD | -Infinity% |
| Zoetis Inc. | 2.56 Billion USD | 87.408% |
| Axsome Therapeutics, Inc. | 15.13 Million USD | -2033.195% |
| Abeona Therapeutics Inc. | -2.44 Million USD | 13310.27% |
| Vertex Pharmaceuticals Incorporated | 738.8 Million USD | 56.3% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 28.42 Million USD | -1035.828% |
| Corcept Therapeutics Incorporated | 7.73 Million USD | -4076.701% |
| Halozyme Therapeutics, Inc. | 127.6 Million USD | -153.022% |
| Blueprint Medicines Corporation | 21.22 Million USD | -1421.269% |
| Insmed Incorporated | 83.24 Million USD | -287.828% |
| TG Therapeutics, Inc. | 39.82 Million USD | -710.735% |
| Incyte Corporation | 62.97 Million USD | -412.702% |
| Emergent BioSolutions Inc. | 328.9 Million USD | 1.837% |